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Abstract
Background:  Baculovirus-expressed HIV-1 Pr55gag Virus-Like Particles (HIV-VLPs) induce
maturation and activation of monocyte-derived dendritic cells (MDDCs) with a production of Th1-
and Th2-specific cytokines.
Results: The analysis of genomic transcriptional profile of MDDCs, obtained from normal healthy
donors and activated by HIV-VLPs, show the modulation of genes involved in the morphological
and functional changes characterizing the MDDCs activation and maturation. Similar data are
obtained using peripheral blood mononuclear cells (PBMCs), without further selection, showing
the feasibility of a direct and “simplified” experimental procedure.
Conclusions: The results here described show that the maturation pattern induced by HIV-VLPs
in ex vivo generated MDDCs, can be observed also in CD14-expressing freshly derived PBMCs, with
the possible identification of genetic predictors of individual response to immunogens.
Introduction
Dendritic cells (DCs) are professional antigen-presenting
cells (APC) able to initiate immune responses [1,2].
Immature DCs are located in peripheral tissues to contin-
uously monitor the environment through the uptake of
particulate and soluble products. Antigen-loaded DCs
acquire a mature phenotype, associated with reduced
endocytic and phagocytic capacities [3-6], and migrate
toward the lymphoid organs to activate naïve T cells,
through upregulated costimulatory molecules such as
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CD40, CD80, CD83 and CD86 [7]. This effect is elicited
by the recognition and binding of pathogen-associated
molecular patterns (PAMPs) to pathogen-recognition
receptors (PRRs) expressed on the DCs, including Toll-
like Receptors (TLRs) and C-type lectins [8-10].
There are two main DC types in human peripheral blood,
known as myeloid DCs (mDCs), the major subset repre-
senting around 80% of blood DCs [11], and plasmacytoid
DCs (pDCs). However, considering that DCs represent
only 1-3% of peripheral blood mononuclear cells
(PBMCs), immature DCs can be obtained in vitro from
peripheral blood monocytes, generating monocyte-
derived DCs (MDDCs) [12]. Additional professional
APCs in PBMCs are represented by Macrophages and B-
cells.
The analysis of the transcription profile, defined as tran-
scriptome, may be highly informative of the molecular
basis underlying the morphological, phenotypical and
functional changes of APCs induced by immunogens. In
particular, the expression pattern of specific sets of genes
upon DC differentiation and maturation has been
reported, showing a great plasticity of the DC transcrip-
tional programs, activated in response to CD40L, LPS and
cocktail of inflammatory cytokines and prostaglandin
(PG) E(2) (CyC) [13,14]. Furthermore, a time-specific
kinetic of response has been observed in MDDC activated
with pathogen components, showing a rapid upregula-
tion of genes associated with the innate arm of the
immune response, followed by induction of adaptive
immune response genes [15-17].
Virus-like particles (VLPs) represent a peculiar form of
subunit vaccine based on viral capsid and envelope pro-
teins which show the ability to self-assemble into highly
organized particulate structures resembling immature
virus particles [18,19]. VLPs can deliver antigenic struc-
tures, such as whole proteins or specific individual
epitopes and have been shown to generally induce more
effective humoral and cellular immune response than
their soluble counterparts [20].
The VLPs developed in our laboratory are based on the
Human Immunodeficiency Virus type 1 Pr55gag precur-
sor protein (HIV-VLPs) and present an entire gp120 mol-
ecule from a Subtype A HIV-1 Ugandan isolate, anchored
through the trans-membrane (TM) portion of the Epstein-
Barr virus (EBV) gp220/350 [21-23].
The HIV-VLPs show a strong in vivo immunogenicity in
Balb/c mice, even in absence of adjuvants, and HIV-1-spe-
cific T cell response (CD4+ and CD8+) as well as cross-
clade neutralizing antibodies have been detected in
immunized animals, at systemic as well as local (vaginal
and intestinal) level [24,25]. These properties suggest the
ability to promote the activation of antigen-presenting
cells (APCs) and a cross-presentation of peptides in asso-
ciation to both MHC class I and -II molecules [26,27].
We have recently shown that baculovirus-expressed HIV-
VLPs are able to induce maturation of MDDCs, resulting
in expression of surface maturation markers as well as
increased production of Th1 polarizing cytokines [28].
Moreover, the HIV-VLP-activated MDDCs show specific
changes in the transcriptional profile of genes involved in
the morphological and functional changes characterizing
the MDDCs activation and maturation [29].
Here we show changes in the gene expression of PBMCs
activated with the baculovirus-expressed HIV-VLPs devel-
oped in our laboratory, in order to compare their tran-
scriptional profiles with the one observed in ex vivo
generated MDDCs. A validation of this approach would
greatly facilitate the screening of immunogenetic analyses




DC culture medium consisted of RPMI 1640 medium
(Life Technologies, Carlsbad, Calif.) supplemented with 2
mM L-glutamine (Sigma), 1% nonessential amino acids
(Life Technologies), 1% sodium pyruvate (Life Technolo-
gies), 50 μM 2-mercaptoethanol (Sigma), 50 μg of gen-
tamicin (Life Technologies) per ml, and 10% fetal calf
serum (Life Technologies).
DC preparation and treatment
Monocyte-derived DCs were generated as described previ-
ously [6], with minor modifications. Briefly, human
peripheral blood mononuclear cells were isolated, from
three independent normal healthy donors, by Ficoll-
Hypaque density gradient centrifugation and were
enriched for CD14+ monocytes by negative selection with
a cocktail of monoclonal antibodies from StemCell Tech-
nologies (Vancouver, British Columbia, Canada), accord-
ing to the instructions of the manufacturer. Typically,
greater than 80% of the cells were CD14+ after enrichment
(data not shown). The isolated monocytes were allowed
to adhere to plastic by plating 106 cells per/ml in RPMI
1640 medium for 2 h. Adherent monocytes were washed
with RPMI 1640 medium and were then cultured for 6
days at 106 cells per/ml in DC culture medium supple-
mented with 50 ng of recombinant GM-CSF (rGM-CSF,
R&D Systems, Minneapolis, Minn.) per ml and 1,000 U of
recombinant IL-4 (rIL-4; R&D Systems, Minneapolis,
Minn.) per ml.BMC Bioinformatics 2008, 9(Suppl 2):S5 http://www.biomedcentral.com/1471-2105/9/S2/S5
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After 6 days in culture, MDDCs were pulsed with 5μg/ml
of HIV-VLPs for 8 hours, for gene microarray analysis, and
for 16 hours for maturation and activation phenotype
analysis. In parallel, PBMCs isolated by Ficoll-Hypaque
density gradient centrifugation from same normal healthy
donors, were pulsed with same concentration of HIV-
VLPs for 12 hours.
Analysis of DC phenotype
MDDCs and PBMCs were incubated for 30 min at 4°C
with murine monoclonal antibodies specific for CD80,
CD83, CD86, HLA-DR and CD14 [PBMCs] (BD Pharmin-
gen, San Diego, CA), washed and then fixed with 2% para-
formaldehyde for analysis with a FACScalibur flow
cytometer (BD Pharmingen). Data analysis was carried
out with FlowJo software (Tree Star Inc., San Carlos, CA).
The cell fraction that responded by upregulation of activa-
tion markers on the cell surface was calculated by overlay-
ing the histograms of treated and untreated cells and
Overton subtraction of the curves.
RNA preparation and microarray hybridization
DCs were harvested, washed twice in PBS and lysed in
350ul RLT buffer with fresh addition of 2-Mercaptoetha-
nol per each well of the 6-well plate. Total RNA was iso-
lated using RNeasy minikits (Qiagen), according to the
manufacturer's protocol, and RNA quality and quantity
was estimated by Agilent Bioanlayzer (Agilent Technolo-
gies, Palo Alto, CA) and NonoDrop. Amplified antisense
RNA (aRNA) was obtained from total RNA (0.5-3 µg) via
two round of in vitro transcription, according the protocol
previously described [30]. 6ug of amplified test samples
aRNA were labeled with Cy5 (Amersham) while the same
amount of reference sample (pooled normal donor
PBMCs) was labeled with Cy3. Test-reference sample pairs
were mixed and co-hybridized to 17K cDNA microarrays
[31].
Microarrays and statistical analyses
Hybridized arrays were scanned at 10-µm resolution on a
GenePix 4000 scanner (Axon Instruments) at variable
PMT voltage to obtain maximal signal intensities with less
than 1% probe saturation. Resulting jpeg and data files
were deposited at microarray data base (mAdb) (http://
nciarray.nci.nih.gov) and retrieved after median centered,
filtering of intensity (>300) and spot elimination (bad
and no signal). Data were further analyzed using Cluster
and TreeView software [31] and Partek Pro software
(Partek). Subsequent low-stringency filtering (80% gene
presence across all experiments and at least one experi-
ment with ratio fold change >3), 3,119 genes were
selected for further analysis. Hierarchical cluster analysis
was conducted on these genes according to Eisen et al.
[32]; differential expressed genes were visualized by
Treeview and displayed according to the central method
[33].
Ethical issues
All human specimens were obtained under informed con-
sent, as approved by the University of Maryland Baltimore
Institutional Review Board.
Results
Baculovirus-HIV-VLP induces a maturation phenotype of 
APCs
Immature MDDCs and freshly derived PBMCs were
obtained from the same three independent donors and
were incubated with 5 μg/ml of HIV-VLPs. After a 8-12 hr-
induction, the expression of surface maturation/activa-
tion markers, such as CD80, CD83, CD86 and HLA-DR,
was examined. The expression of all the four markers was
upregulated in MDDCs as well as in CD14 – expressing
PBMCs by treatment with HIV-VLPs, compared to PBS
(Fig.1). In particular, CD14+ cells are identified as com-
mon, immediate myeloid DC precursors with the ability
to differentiate into interstitial DC (IDC) and Langerhans
cells (LC) [34].
Pattern of MDDCs and PBMCs response to HIV-VLPs
Gene expression profiles were generated from HIV-VLP-
treated MDDC and PBMCs (defined together from now
on, as DCs). Amplified antisense RNA (aRNA) was
obtained from total RNA extracts [30] and hybridized to a
custom-made 17,000 (17K)-clone cDNA microarray chip
enriched with genes relevant to immune function. Strin-
gent filtering were further applied to eliminate genes with
missing value in >20% of all the experiments and >3 fold
Maturation of DCs by baculovirus-expressed HIV-VLPs Figure 1
Maturation of DCs by baculovirus-expressed HIV-
VLPs. Immature MDDCs and PBMCs were incubated in the 
presence of the HIV-VLPs for 16 and 12 hours, respectively. 
The expression of CD80, CD83, CD86 and HLA-DR was 
analyzed on fixed cells by FACScalibur flow cytometer and 
data analysis was carried out with FlowJo software. The 
PBMCs were gated for the CD14 positivity. The results of a 
representative experiment are shown; the shadowed curve 
represents the untreated cells.BMC Bioinformatics 2008, 9(Suppl 2):S5 http://www.biomedcentral.com/1471-2105/9/S2/S5
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change in at least one experiment. The remaining 3,119
genes were thus used for statistic analysis.
Supervised cluster analysis obtained on either MDDCs or
PBMCs samples stimulated with HIV-VLPs shows the seg-
regation of the untreated from the HIV-VLP-treated sam-
ples, at a significance threshold of univariate test <0.005
(Fig. 2A and B). The same analysis, performed using all
the data obtained on both cell populations, show two dis-
tinct clusters with a clear segregation of untreated samples
from the HIV-VLP-treated MDDCs and PBMCs (Fig. 2C).
This result indicates the identification of a similar tran-
scription machinery induced in both ex vivo purified
MDDCs and in vivo “unselected” PBMCs.
Gene expression changes induced in DCs by HIV-VLP 
treatment
The differential gene expression in HIV-VLP-treated DCs,
compared to untreated samples, was considered statisti-
cally significant only when supported by a p<0.005, and
treatment–induced changes in gene profiling were ana-
lyzed using Student's t test. Considering only genes show-
ing at least a 1.5-fold modulation (increase or reduction)
in the transcriptional levels, it has been possible to iden-
tify unique genes in the profile induced by HIV-VLPs
(Table 1).
The HIV-VLP treatment induced in PBMCs the upregula-
tion of 58 genes and the downregulation of 7 genes, indi-
cating that a specific reprogramming of the transcriptional
profile is observed in PBMCs, presumably in the Antigen-
Presenting Cell (APCs) populations. This observation
confirms our previous report, showing that HIV-VLPs
induce a specific transcriptional profile pattern in
MDDCs, distinct from either PBS or LPS treatment [29].
In particular, merging the genes modulated in the analy-
ses performed on MDDCs and PBMCs, a significant set
(>100) of common genes with a differential (up or down
regulation) transcription has been identified. Moreover, a
specific subset of these genes (>25) shows a differential
transcription >2 in both analyses, suggesting the recogni-
tion of a strong transcriptional “signature” pattern com-
mon to both cell target populations (Fig. 3).
Pathways modulation in PBMCs in response to HIV-VLPs
The PBMCs transcriptional profile was analyzed on the
basis of the cellular pathways modulated by the HIV-VLP-
treatment. In respect to the main focus of this study, only
the pathways involved in immune activation have been
evaluated in more detail.
The HIV-VLPs induction of PBMCs results in the activa-
tion of genes associated with antigen presentation func-
tions. A set of cytoskeletal genes that may potentially
mediate shape change and migratory behavior of acti-
vated APCs is also observed. The increase in the expres-
sion of immune cytokines, chemokines, and receptors
contribute to the recruitment of monocytes, DCs, and
macrophages to the site of infection. Moreover, they mod-
ulate both innate and adaptive immune response, includ-
ing the polarization of Th cells, and the down-regulation
of the inflammatory response, which may significantly
interfere with the immune response. The induction of sig-
naling genes and transcription factors may be involved in
preparing the DC to be receptive to regulatory signals in
the lymphatics and lymph nodes. All these categories of
genes are extremely similar to what observed by us upon
HIV-VLP induction of ex vivo derived MDDCs [29].
It is extremely interesting that among the common upreg-
ulated genes, identified in the analyses performed on
MDDCs and PBMCs, some of them are intimately related
to the immune activation (CCL3/MIP-1α, CCL4/MIP-1β,
CCL20/MIP-3α, IL1a, IL8). In particular, CCL3, CCL4 and
CCL20 are chemokines actively participating in the host
response to invading pathogens by regulating the traffick-
ing and activation stage of inflammatory cells, including
the Toll-like receptor signaling pathway. They all exert
Supervised hierarchical clustering of genes differentially  expressed in HIV-VLP-treated cells Figure 2
Supervised hierarchical clustering of genes differen-
tially expressed in HIV-VLP-treated cells. The cluster-
ograms represent an Eisen hierarchical clustering of genes 
differentially expressed (p< 0.005) in HIV-VLPs-treated 
PBMCs (A), MDDCs (B). The comparison between the two 
cell populations is shown in C. The clustering is defined by 
the dendrogram on the top of the clusterogram.BMC Bioinformatics 2008, 9(Suppl 2):S5 http://www.biomedcentral.com/1471-2105/9/S2/S5
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similar effects on monocytes and are potent chemoattract-
ants for lymphocytes and dendritic cells. More specifi-
cally, CCL3 selectively attracting CD8+ Tcells, CCL4
selectively attracting CD4+ Tcells and CCL20 promoting
the adhesion of memory CD4+ Tcells [35-39].
Collectively, the transcriptional profile induced by HIV-
VLPs in freshly drawn PBMCs reflects a significant cellular
and immunological reprogramming of cells directly
involved in the host immune response.
Conclusions
The results here described show that the maturation pat-
tern induced by HIV-VLPs in ex vivo generated MDDCs,
can be observed also in CD14-expressing freshly derived
PBMCs. Moreover, the genomic transcriptional profile
induced by HIV-VLPs in PBMCs shows the activation of
unique genes and cellular pathways, reflecting a distinc-
tive cellular and immunological reprogramming of circu-
lating cells deputed to trigger the host immune response.
Table 1: Pathways involved in the HIV-VLPs-induced PBMCs.  The pathways are derived from the BioCarta through the Cancer 
Genome Anatomy Project at http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways. Genes with at least a 1.5-fold modulation (up or 
downregulation) have been taken into consideration.
Pathways VLP vs PBS 
Up-regulated
Pathways VLP vs PBS 
Down-regulated
Antigen processing and presentation CTSL ECM-receptor interaction CD36
Cell cycle, proliferation, cell death I L 3 R A                                                         
S M O X                                                         
B CL2                                                         
G 0 S2                                                        
IER3                         
Cytokine-cytokine receptor interaction IL1R2
Cell shape & extracellular matrix S E R P I N B 2                                                         
LIMK2                         
Chaperones modulate interferon Signaling 
Pathway
HSPA7
Chemokine and cytokines IL6                                                        
P B F E 1                                                         
PBX3                         
Cytokine Network I L1 -A                                                         
IL1-B                         
Cytokine-cytokine receptor interaction C C L 1 8                                                         
C C L 2 0                                                         
C C L 7                                                         
C X C L 1                                                         
C X C L 2                                                         
C X C L 3                                                         
C X C L 6                                                         
C X C L 1 3                                                         
INHBA                         
Immune response ACTN1                         
Membrane proteins A Q P 9                                                         
E M R 1                                                         
S L C 2 5 A 3 7                                                         
SLCO4A1                         
Transcription MAD                         
Selective expression of chemokine receptors 
during T-cell polarization/Toll-like receptor 
signaling pathway
CCL4  (MIP1β)                                                                                                               
CCL3  (MIP  1α)                                                                                                               
IL8                         
Genes with a differential expression identified in both HIV- VLP- treated MDDCs and PBMCs Figure 3
Genes with a differential expression identified in both 
HIV-VLP- treated MDDCs and PBMCs. The level of dif-
ferential expression for each of the common genes identified 
in both analyses is shown. The gray boxes include the genes 
showing a differential expression >2 in both MDDCs and 
PBMCs induced with HIV-VLPs.BMC Bioinformatics 2008, 9(Suppl 2):S5 http://www.biomedcentral.com/1471-2105/9/S2/S5
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A supervised Eisen's clustering analysis confirms the spe-
cificity of the observation, given that the PBMCs samples,
derived from the HIV-VLP treatment, cluster together indi-
cating that the pattern of specifically modulated genes is
consistent all across the analyzed samples. A comparison
with the pattern induced by HIV-VLP treatment in ex vivo
generated MDDCs identifies a cluster of genes whose
expression is similarly modulated, indicating that a spe-
cific transcriptional signature is found between ex vivo
generated MDDCs and “unselected” PBMCs.
Among the pathways and specific genes activated in
PBMCs treated with HIV-VLPs, those directly involved in
the biological functions as antigen presenting cells (APCs)
have been analyzed in detail. The functional maturation
and activation of CD14-positive cell population present
in PBMCs by HIV-VLPs has been shown and, in particular,
the activation of genes involved in cellular control (prolif-
eration, differentiation, migration and homeostasis) as
well as in functional activity (antigen presentation, T cell
activation and Th polarization) has been observed.
These results are extremely interesting, indicating the sen-
sibility and the specificity of the gene transcriptional pro-
file analysis for identifying in PBMCs, regardless the
heterogeneity of cell populations unrelated to the host
immune response, a cluster of genes whose transcription
is specifically modulated in response to an antigen, such
as the HIV-VLPs. The cell populations likely involved in
this process are the blood DCs (myeloid DCs, mDC; and
plasmacytoid DCs, pDCs), as well as the additional pro-
fessional APCs such as Macrophages and B-cells. Their
specific individual involvement in the observed reponse
will be further evaluated.
These results confirm the data obtained by HIV-VLP treat-
ment of selected ex vivo generated MDDCs [29]. In this
regard, the presence of transcriptionally modulated genes
common to both analyses strongly suggest the possibility
of identifiyng a genomic signature in PBMCs induced by
an antigen, without the need of purification and ex vivo
selection of DCs. If the reported data will be confirmed on
a larger scale, the possibility of screening the donor sus-
ceptibility to an antigen treatment using PBMCs would
greatly simplify the identification of “responsive” vac-
cinees and the understanding of eventual failures in indi-
viduals enrolled in clinical trials.
Microarray approach allows quantitative and simultane-
ous analysis of gene expression of a large amount of genes
and the systematic studies of expression patterns are
extremely useful for identify molecular events and key
pathways involved in cellular functions induced by spe-
cific stimuli. In particular, data on the global pattern of
gene expression underlying the modifications induced by
HIV-VLPs in PBMCs, at early stages of antigen administra-
tion, may be extremely helpful for the identification of
exclusive activation markers to trace the biological effects
of modifications/optimizations of the HIV-VLP vaccina-
tion strategy.
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